The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Is CAR T-cell therapy a safe and effective treatment option for R/R T-ALL and lymphoma?
During the 2023 Society of Hematologic Oncology (SOHO) Congress, the ALL Hub spoke to Maksim Mamonkin, Baylor College of Medicine, Houston, US. We asked, Is chimeric antigen receptor (CAR) T-cell therapy a safe and effective treatment option for relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and lymphoma.
Is CAR T-cell therapy a safe and effective treatment option for R/R T-ALL and lymphoma?
Firstly, Mamonkin discusses recent progress made in the development and evaluation of CAR T-cell therapies in T-ALL and lymphoma. He highlights several strategies that have yielded encouraging results, including autologous CD7-directed CAR T-cell therapies utilizing various methods, such as gene editing to prevent the risk of fratricide in China, CRISPR-based editing of anti-CD7 CAR T cells in the UK, and unedited CD7-directed CAR T cells in the US.
He goes on to mention challenges in the field, including preventing the risk of fratricide, reducing ablation of circulating endogenous CAR T cells, T-cell aplasia, and antigen escape. One alternative approach currently being investigated to overcome antigen escape is the use of different antigen targets, such as CD5-directed CAR T cells. Both CD7 and CD5-directed CAR T-cell therapies are paving the way in the treatment of R/R T-ALL.
